Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Gene J. Abel who wrote (1869)	9/29/1997 5:23:00 AM
From: James Baker	of 6136

Margie and Gene, I own AGPH and hope that the stock and Viracept cont to do well. A few comments on your last two posts. In my experience the news media never reads the program and abstracts and writes a story before the paper is formally presented at the scientific meeting. In a way it would be improper for them to do so. Studies can change between submission of an abstract and meeting time/presentation (additional data etc). Some are even withdrawn. I agree with you that giving such a small preliminary study undue headline and importance is a journalistic shame. Hype over good reporting. But there are not demons everywhere just becasue news is counter our hopes. Time and more data will sort out the Viracept resistance truth. Your comments on open label, not double blind controlled etc are not really relevent here. Resistance is not a matter of subjective opinion but should be a measured lab result. Finally your comment that Merck sponsors Medscape news about ICAAC so it will not have anything good about AGPH. I have attended many conferences funded by "unrestricted educationsl grants" and speakers frequently state their preferred drug is some other company's product. Jim

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next